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Summary
Background Live attenuated inﬂ uenza vaccines have been shown to signiﬁ cantly reduce inﬂ uenza in diverse 
populations of children, but no eﬃ  cacy studies have been done in resource-poor tropical settings. In Senegal, we 
assessed the eﬃ  cacy and safety of a live attenuated inﬂ uenza vaccine based on Russian-derived master donor viruses 
and licensed as a single dose.
Methods In this double-blind, placebo-controlled, parallel group, single-centre trial done near Niakhar, Senegal, 
generally healthy children aged 2–5 years were randomly allocated (2:1) to receive a single intranasal dose of masked 
trivalent live attenuated inﬂ uenza vaccine or placebo. The allocation sequence was computer-generated by PATH with 
block sizes of three. The manufacturer provided vaccine and placebo in coded vials to preserve blinding. Participants 
were monitored through the predictable inﬂ uenza season in Senegal for adverse events and signs and symptoms of 
inﬂ uenza using weekly home visits and surveillance in clinics. The primary outcome was symptomatic laboratory-
conﬁ rmed inﬂ uenza caused by any strain and occurring from 15 days post-vaccination to the end of the study. The 
primary analysis was per protocol. This study is registered with ClinicalTrials.gov, number NCT01854632.
Findings Between May 23, and July 1, 2013, 1761 children were randomly assigned, 1174 to receive live attenuated 
inﬂ uenza vaccine and 587 to receive placebo. The per-protocol set included 1173 vaccinees and 584 placebo recipients 
followed up to Dec 20, 2013. Symptomatic inﬂ uenza was laboratory-conﬁ rmed in 210 (18%) of 1173 recipients of live 
attenuated inﬂ uenza vaccine and 105 (18%) of placebo recipients, giving a vaccine eﬃ  cacy of 0·0% (95% CI –26·4 to 20·9). 
Adverse events were balanced between the study groups. Two girls who had received live attenuated inﬂ uenza vaccine 
died, one due to anasarca 12 days postvaccination and one due to malnutrition 70 days postvaccination.
Interpretation Live attenuated inﬂ uenza vaccine was well tolerated in young children in Senegal, but did not provide 
protection against inﬂ uenza. Further study in such populations, which might experience extended periods of 
inﬂ uenza circulation, is warranted.
Funding US Centers for Disease Control and Prevention and Bill & Melinda Gates Foundation.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
Globally, lower respiratory infection remains the leading 
cause of death in children younger than 5 years,1–3 and 
inﬂ uenza virus infections can be an important contributor 
to serious lower respiratory disease.4 Live attenuated 
inﬂ uenza vaccines are an attractive option for young 
children in low-resource settings. In US trials done before 
this trial was initiated, live attenuated inﬂ uenza vaccines 
had shown superior eﬃ  cacy to inactivated vaccines among 
young children and might be cross-protective against 
drifted inﬂ uenza viruses.5,6 Live attenuated inﬂ uenza 
vaccines are likewise attractive from a manufacturing 
perspective because higher yields, a simpler puriﬁ cation 
process, and quicker lot release should lower the cost of 
production of live attenuated inﬂ uenza vaccines relative to 
inactivated vaccines.7 Finally, live attenuated inﬂ uenza 
vaccines might be more feasible given their intranasal 
administration and potential protection with a single dose.8
In Senegal, there are no recommendations for routine 
inﬂ uenza vaccination of children, and generally only 
trivalent inactivated inﬂ uenza vaccine of WHO-
recommended northern hemisphere formulation has 
been available in the country for use in vaccination of 
pilgrims to the Hajj. The National Inﬂ uenza Center of 
Senegal has been undertaking inﬂ uenza surveillance for 
more than 20 years and has accumulated data that 
inﬂ uenza, especially type A, occurs in association with 
the rainy season9 (typically between July and September) 
and can circulate widely, especially among children.
Under the Global Pandemic Inﬂ uenza Action Plan to 
Increase Vaccine Supply, the WHO leads a programme 
to enhance regional access to inﬂ uenza vaccines by 
supporting developing country vaccine manufacturers.10 
Serum Institute of India, Ltd (Pune, India) participated 
in this initiative and developed a reassortant live 
attenuated seasonal inﬂ uenza vaccine based on 
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A/Leningrad/17 and B/USSR/60 master donor viruses. 
To understand how live attenuated inﬂ uenza vaccines 
such as this might perform in young children in 
resource-limited tropical settings in Africa, we assessed 
the eﬃ  cacy of Serum Institute of India’s trivalent live 
attenuated inﬂ uenza vaccine, which is licensed as a 
single dose for prevention of inﬂ uenza, in Senegal.
Methods
Study design and participants
This double-blind, placebo-controlled, parallel group, 
single-centre trial was done in the rural area comprising 
the Niakhar Demographic Surveillance System, about 
110 km southeast of Dakar, Senegal. Generally healthy 
children aged 2–5 years were eligible if a parent was willing 
to provide written informed consent and was not expecting 
to migrate out of the area during the study period. 
Informed consent was obtained through a well established 
two-step process in accordance with established social 
structures and cultural norms in this population. First, the 
investigator held group meetings in communities of the 
study area to obtain village permission for study conduct. 
Second, a list of eligible children was constructed using 
demographic surveillance system data, and parents of 
eligible children were approached by trained study staﬀ  
during the month prior to study initiation to provide them 
with information about the upcoming research study. 
Those interested in participating were given dates and 
locations of enrollment days at their locale. On days of 
enrolment, trained study staﬀ  reviewed study information 
with presenting parents and children, and children were 
enrolled consecutively as parents provided written 
informed consent and children were determined to be 
eligible to participate. Trained study physicians were 
present on all enrolment days. Exclusion criteria included 
serious active medical conditions. Acute malnutrition is 
common in Senegal, particularly during the typical 
inﬂ uenza season from June through October before the 
harvest. Therefore, malnourished children were not 
speciﬁ cally excluded. Eligibility criteria are listed in the 
appendix (p 1).
Ethics review was provided by the National Ethics 
Committee for Health Research (Senegal Ministry of 
Health and Social Welfare) and Western Institutional 
Review Board. The study was done in accordance with 
the principles of the Declaration of Helsinki (2008) and 
in compliance with Good Clinical Practice guidelines.
Randomisation and masking
Participants were randomly allocated (2:1) to receive the 
live attenuated inﬂ uenza vaccine or placebo. The allocation 
sequence was computer-generated by PATH with block 
sizes of three. The sequence was delivered to Serum 
Institute of India where vaccine and placebo were labelled 
before shipping to Senegal for use in the ﬁ eld. Vaccine and 
placebo were identical in appearance and vials containing 
the study products were labelled only with a clinical trial 
label and unique allocation numbers to preserve blinding.
 Research in context
Evidence before this study
We searched PubMed from Jan 1, 1980, to Jan 1, 2016, for 
eﬃ  cacy trials assessing protection by live attenuated inﬂ uenza 
vaccines among children using the search terms, “human 
inﬂ uenza”, “vaccines, attenuated”, and “children”. Live 
attenuated inﬂ uenza vaccines have been studied mainly in 
developed countries in Europe, Asia, and in the USA, but one 
study has included children aged 6 months to 36 months 
of age from sites in South Africa. In nearly all studies, 
A/Ann Arbor-based live attenuated inﬂ uenza vaccines provided 
signiﬁ cant protection. Russian-derived live attenuated inﬂ uenza 
vaccines used among young children had been studied primarily 
from 1986 to 1991 in ﬁ ve trials in the Soviet Union and Cuba. 
These studies used serological conﬁ rmation of illness and were 
done before introduction of Good Clinical Practice standards for 
the designing, conducting, recording, and reporting of trials. 
Moreover, except for the companion study in Bangladesh, no 
eﬃ  cacy trials of Russian-derived live attenuated inﬂ uenza 
vaccines have been done in developing country settings. The 
only study of clinical protection of Serum Institute of India’s live 
attenuated inﬂ uenza vaccines was an observational case-control 
study of the eﬀ ectiveness of one dose of its monovalent live 
attenuated inﬂ uenza vaccines containing vaccine virus 
antigenically similar to pandemic A/H1N1 (2009).
Added value of this study
To the best of our knowledge, our trial is the ﬁ rst randomised 
trial of any live attenuated inﬂ uenza vaccines in tropical 
developing Africa, and our results indicate that children in this 
population were not protected with one dose. Our results 
point to the need for more study of live attenuated inﬂ uenza 
vaccines in impoverished populations in Africa to understand 
how well live attenuated inﬂ uenza vaccines do and can best be 
used to provide protection to young children.
Implications of all the available evidence
The results of this study should be viewed in light of data from 
early studies in developed populations and the results of our 
companion study in Asia in which live attenuated inﬂ uenza 
vaccines provided moderately high protection to this young 
child age group. Counter to this ﬁ nding is the fact that 
observational eﬀ ectiveness studies in the USA in 2013–14 
found a similar absence of eﬃ  cacy of live attenuated inﬂ uenza 
vaccines against A/H1N1 (2009) in young children. Live 
attenuated inﬂ uenza vaccines are easy to administer and 
might be the optimal choice for child populations in 
developing populations. However, further study in such 
populations, which might experience extended periods of 
inﬂ uenza circulation, is warranted.
See Online for appendix
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Procedures
Study products were lyophilised live attenuated inﬂ uenza 
vaccine of 2012–13 Northern Hemisphere formulation 
(Nasovac-S, Serum Institute of India, Pune, India; 
lot 167E2002) containing A/California/7/2009 (H1N1)-like, 
A/Victoria/361/2011 (H3N2)-like, and B/Wisconsin/1/2010 
(Yamagata lineage)-like reassortants. Matched placebo 
was identical to vaccine in appearance and content but 
was missing viral components (Serum Institute of India; 
lot E9001PCB). A single 0·5 mL dose of either was 
administered intranasally (divided evenly per nostril) to 
each participant using Wolfe-Tory mucosal atomiser 
devices. Lyophilised vaccine was stored at 2–8°C until 
reconstitution with diluent of ambient temperature. 
Administration after reconstitution was immediate.
Participant follow-up was planned from June, 2013, 
until December, 2013, during which participants were 
monitored weekly through home visits by trained ﬁ eld 
workers. On day 7 postvaccination, participants were 
assessed for solicited reactions and unsolicited adverse 
events occurring since vaccination, and on day 28 
for unsolicited adverse events. Adverse events were 
documented by ﬁ eld workers using standardised data 
collection forms after interviews with parents at each 
visit. Throughout study follow-up, standardised criteria 
were used to identify participants with signs and 
symptoms of inﬂ uenza. Additional criteria were used to 
refer participants with medically important illness to a 
study physician for further evaluation. These physicians 
provided treatment as per the standard of care in Senegal 
and assessed participants for study outcomes of clinical 
inﬂ uenza, protocol-deﬁ ned wheezing illness, and serious 
adverse events. For all participants with signs or 
symptoms of inﬂ uenza, both a nasal swab and a 
pharyngeal swab specimen were collected and pooled.
A subset of participants already enrolled in the main 
trial were additionally consented to participate in a vaccine 
infectivity and extended safety subset to assess the ability 
of cold-adapted vaccine viruses to replicate in the nasal 
passages of children in this population in which ambient 
daily temperatures regularly exceed 40ºC during the 
period of trial vaccinations and to provide a more detailed 
description of vaccine safety during the 7 days 
postvaccination in this low-resource population. For this 
analysis, both a nasal swab and a pharyngeal swab 
specimen were collected prevaccination and on days 2 and 
4 postvaccination from all subset participants. Detailed 
solicited reactions and unsolicited adverse events were 
also collected on standard data collection forms by ﬁ eld 
workers through interview with parents/guardians.
Outcomes
The primary eﬃ  cacy endpoint was symptomatic 
laboratory-conﬁ rmed inﬂ uenza caused by any virus type, 
including those not included in the vaccine, and 
occurring from 15 days post vaccination to the end of the 
study in December, 2013. Symptomatic inﬂ uenza was 
deﬁ ned as sudden onset of measured fever (>37·5ºC 
axillary) or subjectively reported feverishness and a 
cough or sore throat. Laboratory conﬁ rmation (type and 
subtype or lineage) was deﬁ ned as detection of seasonal 
inﬂ uenza virus in a swab specimen. Specimens were 
tested at Senegal’s National Inﬂ uenza Centre Laboratory 
at the Institut Pasteur de Dakar for the presence 
of inﬂ uenza virus by real-time RT-PCR using methods 
and reagents, including standard seasonal inﬂ uenza 
oligonucleotide primers and probes, provided by the 
Inﬂ uenza Division of the US Centers for Disease Control 
and Prevention (CDC). Additionally, although not 
protocol-speciﬁ ed, all inﬂ uenza-positive specimens from 
symptomatic cases occurring within 1 month of 
vaccination were shipped to the US CDC and tested 
post-hoc by real-time RT-PCR using CDC’s oligonu-
cleotide primer-probe sets speciﬁ c for live attenuated 
inﬂ uenza virus A and live attenuated inﬂ uenza virus B, 
as was done for specimens from the vaccine infectivity 
subset. Antigenic characterisation of about 20% of 
positive specimens was done at CDC. Secondary eﬃ  cacy 
endpoints were symptomatic laboratory-conﬁ rmed 
inﬂ uenza matched to vaccine and inﬂ uenza strain-
speciﬁ c symptomatic inﬂ uenza.
Safety endpoints included solicited local and systemic 
reactions (nasal congestion, runny nose, stuﬀ y nose, ear 
pain, cough, sore throat, headache, fever, tachypnoea, 
muscle or joint pain, chills, irritability or decreased 
activity, and vomiting), unsolicited adverse events and 
serious adverse events, and protocol-deﬁ ned wheezing 
illness. Protocol-deﬁ ned wheezing illness was deﬁ ned as 
an illness meeting physician evaluation criteria (fever 
>38ºC axillary, tachypnoea >40 breaths per min, ear pain, 
seizure or convulsions, or any other condition believed to 
warrant physician evaluation) and characterised by a 
Figure 1: Trial proﬁ le
LAIV=live attenuated inﬂ uenza vaccine.
1886 assessed for eligibility
1761 randomised
125 excluded as they did not 
meet eligibility criteria
587 allocated to placebo
587 received placebo
584 included in the per-protocol 
eﬃcacy analysis
3 excluded
2 lost to follow-up during 
ﬁrst 14 days
1 insuﬃcient information 
about eligibility
1174 allocated to LAIV
1174 received LAIV
1173 included in the per-protocol 
eﬃcacy analysis
1 excluded
1 lost to follow-up during 
ﬁrst 14 days
Articles
e958 www.thelancet.com/lancetgh   Vol 4   December 2016
long, high-pitched whistling or musical sound on 
expiration heard by auscultation over the lung ﬁ elds. 
Severity of protocol-deﬁ ned wheezing illness was graded 
by study physicians as mild (wheezing illness without 
other ﬁ ndings associated with disease of moderate or 
greater severity), moderate (nasal ﬂ aring, chest in-
drawing, or pulse oximetry 90–95%), severe (dyspnoea at 
rest causing inability to perform usual social and 
functional activities or pulse oximetry <90%), or life 
threatening (per physician’s medical opinion).
Swab specimens from the vaccine infectivity subset 
were tested at the US CDC by real-time RT-PCR ﬁ rst for 
the presence of inﬂ uenza virus using standard seasonal 
inﬂ uenza oligonucleotide primers and probes. Positive 
specimens in the vaccine group were further tested for 
the presence of live attenuated inﬂ uenza vaccine by 
real-time RT-PCR using oligonucleotide primers and 
probes designed to detect internal virus genes speciﬁ c to 
the A/Leningrad/134/17/57 (H2N2) and B/USSR/60/69 
master donor viruses used to create the cold-adapted 
reassortants contained in the vaccine.
Statistical analysis
The primary objective was to estimate the eﬃ  cacy of live 
attenuated inﬂ uenza vaccine in reducing the rate of 
symptomatic laboratory-conﬁ rmed inﬂ uenza regardless 
of vaccine match among children receiving live attenuated 
inﬂ uenza vaccine. Vaccine eﬃ  cacy was deﬁ ned as one 
minus the relative rate (times 100%) of inﬂ uenza in the 
live attenuated inﬂ uenza vaccine group compared with 
that in the placebo group. A Cox proportional hazards 
model with censoring at time of ﬁ rst endpoint was ﬁ tted 
to estimate the relative rate and its 95% CI. The protocol 
speciﬁ ed that endpoints occurring within 2 weeks 
postvaccination were not counted to allow suﬃ  cient time 
for development of the immune response and to ensure 
that any vaccinees with non-inﬂ uenza acute respiratory 
illness during this period would not be misclassiﬁ ed if 
vaccine virus was identiﬁ ed by real-time RT-PCR using 
seasonal inﬂ uenza primer-probe sets. Secondary eﬃ  cacy 
endpoints were similarly analysed. Primary eﬃ  cacy 
analyses were done on a per-protocol basis and included 
all children who met eligibility criteria, were randomised, 
received one dose of study vaccine, and contributed at 
least one day of person-time. Supportive analyses were 
also done on the total vaccinated cohort of all randomised 
participants who received a dose of vaccine or placebo, 
counting endpoints occurring at any time postvaccination. 
Eﬀ ect of previous receipt of trivalent inactivated vaccine 
on eﬃ  cacy was explored in post-hoc analyses, as was the 
eﬀ ect of malnutrition, with adjustment for grade of 
malnutrition. Grades for weight-for-age, height-for-age, 
and weight-for-height were based on calculated Z scores 
and categorised as mild (–2 to <–1), moderate (–3 to <–2), 
or severe (<–3).11,12
Safety in the total vaccinated cohort and the extended 
safety subset was described as the proportion of 
Live attenuated 
inﬂ uenza 
vaccine 
(n=1174)
Placebo 
(n=587)
Study completion
Followed up to Dec 20, 2013 1148 (98%) 574 (98%)
Lost to follow-up 10 (1%) 7 (1%)
Temporary migration 14 (1%) 6 (1%)
Died 2 (<1%) 0
Age, months 47·7 (13·2) 47·3 (13·5)
Age group (years)
2–<3 278 (24%) 150 (26%)
3–<4 310 (26%) 157 (27%)
4–<5 323 (28%) 145 (25%)
5–<6 263 (22%) 135 (23%)
Sex
Male 610 (52%) 297 (51%)
Female 564 (48%) 290 (49%)
Height and weight
Height (cm) 98·2 (9·5) 98·0 (9·4)
Weight (kg) 14·4 (2·7)  14·3 (2·8)
Underweight: weight-for-age malnutrition grade*
None 641 (55%) 319 (54%)
Mild 333 (28%) 166 (28%)
Moderate 162 (14%) 75 (13%)
Severe 38 (3%) 27 (5%)
Stunting: height-for-age malnutrition grade*
None 608 (52%) 311 (53%)
Mild 360 (31%) 176 (30%)
Moderate 153 (13%) 72 (12%)
Severe 53 (5%) 28 (5%)
Wasting: weight-for-height malnutrition grade*
None 604 (51%) 289 (49%)
Mild 192 (16%) 98 (17%)
Moderate 98 (8%) 54 (9%)
Severe 41 (4%) 21 (4%)
Unknown† 239 (20%) 125 (21%)
History of chronic illness, including 
asthma or wheezing illness‡
1 (<1%) 0
Receipt of trivalent inactivated inﬂ uenza vaccine in previous ﬁ eld trials 
at site
Never 580 (49%) 285 (49%)
In mid-2009 (containing 
A/Brisbane/59/2007 [H1N1]-like virus)
65 (6%) 24 (4%)
In mid-2010 or mid-2011 (containing 
A/California/7/2009 [H1N1]-like virus)
512 (44%) 272 (46%)
Previous receipt could not be 
determined
17 (1%) 6 (1%)
Receipt of oral polio vaccine in past 30 days
Yes 817 (70%) 413 (70%)
No 357 (30%) 174 (30%)
Data are n (%) or mean (SD). *Based on Z score: mild (–2 to <–1), moderate 
(–3 to <–2), severe (<–3). †Weight for height Z score cannot be calculated for 
children 60 months or older and so is categorised as unknown. ‡One child in the 
live attenuated inﬂ uenza vaccine group reported a history of asthma.
Table 1: Participant completion rates and baseline characteristics
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participants in each study group experiencing reactions 
or events of any severity (and by severity grade) with its 
corresponding exact 95% CI. Fisher’s exact test was used 
to compare proportions of reactions of any severity grade 
between study groups. Participant safety was also 
overseen by an independent safety monitoring committee 
convened by PATH.
Assuming 60% eﬃ  cacy, 57 total primary endpoints 
were required to test the hypothesis that live attenuated 
inﬂ uenza vaccine eﬃ  cacy was greater than 0% with a 
one-sided type I error of less than 2·5% and power of at 
least 90%. Based on this number and assuming a 
6% incidence rate and 90% evaluability, a total sample 
size of 1761 enrolled subjects was estimated.
Data were analysed with SAS version 9.3.
This study is registered with ClinicalTrials.gov, number 
NCT01854632.
Role of the funding source
This work was funded through a Cooperative Agreement 
to PATH from the US Centers for Disease Control and 
Prevention (U01IP000476). Supplementary funding from 
the Bill & Melinda Gates Foundation to PATH (OPP1017334) 
supported statistical analyses. The ﬁ ndings and con-
clusions in this report are those of the authors and do not 
necessarily represent the oﬃ  cial position of the US CDC, 
Gates Foundation, or PATH. All authors had full access to 
all the data in the study and JCV had ﬁ nal responsibility 
for the decision to submit for publication.
Results
Between May 23, and July 1, 2013, 1761 children were 
enrolled and randomised; 1174 were allocated to receive 
study vaccine and 587 to receive placebo (ﬁ gure 1). Nearly 
all (1757) contributed person-time to the primary 
(per-protocol) analysis of eﬃ  cacy. Retention was very 
high, with 1722 (98%) being monitored to the end of the 
follow-up period, Dec 20, 2013 (table 1). Children who 
additionally gave consent into the vaccine infectivity and 
extended safety subset had their day 0 swabs taken 
between May 23 and June 5.
Baseline characteristics were similar in the two study 
groups (table 1). A substantial proportion of participants 
were malnourished to some extent, with 46% 
Figure 2: Inﬂ uenza circulation in Niakhar, by type and subtype or lineage, from week 22 to week 51 during the period of the trial
The graph is a stacked column chart where numbers of positive detections for each strain each week are stacked in the graph and can be visually summed. Study 
vaccinations occurred from week 22 to week 28. Laboratory testing data from the trial indicated that B circulation was of mixed lineage from week 22 through 35 but 
became almost only Victoria lineage (unmatched to vaccine) thereafter. Inset show inﬂ uenza circulation in Senegal, by type and subtype, during the entire year of the 
trial, 2013, as measured by the Senegal National Inﬂ uenza Center. Note: determination of B lineage was not standard practice for national surveillance in 2013. Data 
from WHO Flunet.
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underweight, 48% stunted, and 36% showing wasting. 
Otherwise, participants had few identiﬁ able medical 
issues. Only one child, in the live attenuated inﬂ uenza 
vaccine group, had a reported history of asthma.
Type B inﬂ uenza viruses of both lineages were already 
circulating in Senegal by the beginning of the trial 
(ﬁ gure 2). At the trial site, the circulation of Victoria 
lineage B virus (unmatched to vaccine) intensiﬁ ed as the 
season progressed. Midway through the trial, H1N1pdm09 
appeared and circulated extensively until the end of the 
study period. H3N2 circulation was negligible.
Inﬂ uenza incidence among young children in this study 
was high. In the primary analysis, 210 endpoints of 
symptomatic laboratory-conﬁ rmed inﬂ uenza were reached 
among vaccine recipients (18%) and 105 were reached 
among placebo recipients (18%), yielding an eﬃ  cacy point 
estimate of 0·0% (95% CI –26·4 to 20·9%; table 2). 
Analyses of secondary endpoints caused by vaccine-
matched strains and by speciﬁ c type and subtype or lineage 
likewise revealed no statistical evidence for vaccine eﬃ  cacy. 
79 (7%) endpoints of H1N1pdm09 were noted in the 
vaccine group and 36 (6%) in the placebo group; 20 (2%) 
endpoints of vaccine-matched B in the vaccine group and 
11 (2%) in the placebo group; and 115 (10%) endpoints of 
vaccine-mismatched B in the vaccine group and 62 (11%) 
in the placebo group. Only three (<1%) endpoints of H3N2, 
all in the vaccine group, were reached. In a post-hoc 
analysis of eﬃ  cacy against all vaccine-matched strains 
using the per-protocol dataset, among children previously 
vaccinated with trivalent inactivated inﬂ uenza vaccine 
(containing A/California/7/2009) in 2010 or 2011 (average 
age of this subgroup, 4·4 years), live attenuated inﬂ uenza 
vaccine eﬃ  cacy was –28·4% (95% CI –108·7 to 19·9) 
compared with 15·4% (–27·5 to 43·4) among children with 
no previous receipt of trivalent inactivated inﬂ uenza 
vaccine (average age of this subgroup, 3·5 years). 
Additional post-hoc analyses in which we stratiﬁ ed primary 
and secondary analyses by age groups or measures of 
malnutrition also did not show any signiﬁ cant eﬃ  cacy for 
any measure (data not shown).
Detection of at least one strain of vaccine virus was 
conﬁ rmed in 55 (83%) of 66 live attenuated inﬂ uenza 
vaccine recipients postvaccination (table 3). Virus 
detection was highest on day 2 postvaccination. Live 
attenuated inﬂ uenza vaccine-A/H3N2 and live attenuated 
inﬂ uenza vaccine-B viruses were detected postvaccination 
among 34 (52%) and 42 (66%) of recipients, respectively. 
Live attenuated inﬂ uenza vaccine-A/H1N1pdm09 was 
detected among only 14 (22%) of recipients.
Per-protocol population Total vaccinated cohort
Live attenuated 
inﬂ uenza vaccine 
(n=1173)
Placebo 
(n=584)
Vaccine eﬃ  cacy 
(95% CI)*
Live attenuated 
inﬂ uenza vaccine 
(n=1174)
Placebo 
(n=587)
Vaccine eﬃ  cacy 
(95% CI)*
Primary virological endpoint
All strains* 210 (18%) 105 (18%) 0·0% (–26·4 to 20·9) 225 (19%) 107 (18%) –6·5% (–34·1 to 15·4)
Secondary virological endpoint
All vaccine-matched strains† 100 (9%) 47 (8%) –6·1% (–50·0 to 25·0) 114 (10%) 47 (8%) –22·6% (–72·2 to 12·7)
H1N1 79 (7%) 36 (6%) –9·7% (–62·6 to 26·1) 79 (7%) 36 (6%) –9·9% (–62·9 to 25·9)
H3N2‡ 3 (<1%) 0 ·· 10 (1%) 0 ··
B (Yamagata lineage, matched 
to vaccine)
20 (2%) 11 (2%) 9·5% (–88·9 to 56·6) 28 (2%) 11 (2%) –27·7% (–156·5 to 36·4)
B (Victoria lineage, unmatched 
to vaccine)
115 (10%) 62 (11%) 7·3% (–26·3 to 31·9) 118 (10%) 64 (11%) 7·7% (–25·1 to 31·9)
Data are n (%). *1 minus the relative rate x 100%; relative rate was estimated using a Cox proportional hazards model. †Only the ﬁ rst laboratory-conﬁ rmed inﬂ uenza-like illness 
occurring more than 14 days postvaccination was counted in the all strains and all vaccine-matched strains analyses. ‡H3N2: none of the three live attenuated inﬂ uenza vaccine 
cases have been tested for live attenuated inﬂ uenza vaccine vs wild-type virus. One case occurred 15 days postvaccination and the other two cases, one of which could not be 
conﬁ rmed by the WHO Collaborating Center at the US CDC as H3N2, occurred more than 100 days postvaccination. The seven additional H3N2 cases added in the total vaccinated 
cohort occurred during the 14-day postvaccination period; six of these were conﬁ rmed to be live attenuated inﬂ uenza vaccine type inﬂ uenza A. 
Table 2: Symptomatic laboratory-conﬁ rmed inﬂ uenza outcomes among children aged 2–5 years in Senegal receiving live-attenuated inﬂ uenza vaccine or 
placebo and estimated vaccine eﬃ  cacy
Day 2 Day 4* Either day
LAIV-A/H1N1 12/65 (19%) 3/66 (5%) 14/65 (22%)
LAIV-A/H3N2 31/65 (48%) 18/66 (27%) 34/65 (52%)
LAIV-B 34/65† (52%) 28/65 (43%) 42/64 (66%)
Any 48/65 (74%) 39/66 (59%) 55/66 (83%)
Data are n/total n (%). Specimens test-inconclusive for a particular strain were 
removed from the denominator of the respective table cell, except for the Any 
row where the specimen is counted in the denominator if it was test-positive for 
one of the other three vaccine strains. LAIV=live attenuated inﬂ uenza vaccine. 
*On day 4, three specimens had LAIV-A detected but subtype was undetermined. 
†On day 2, four specimens were positive using the seasonal inﬂ uenza B primers 
but negative using the LAIV-type B primers. On day 4, one of these four was then 
negative using both seasonal and LAIV-B primers, and the other three were then 
positive using both seasonal and LAIV-B primers. Only one participant in the 
placebo group (n=34) was ever positive for inﬂ uenza, with only that participant’s 
day 0 specimen testing positive for seasonal inﬂ uenza B only. 
Table 3: Detection of vaccine virus on day 2 and day 4 postvaccination 
among vaccine recipients in the vaccine infectivity subset
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One child in the live attenuated inﬂ uenza vaccine 
group experienced mild epistaxis in the 30 min 
postvaccination. In the 7 days postvaccination, the most 
common solicited events reported overall were runny 
nose (296; 17%), cough (172; 10%), and nasal congestion 
(57; 3%). Nearly all reactions were mild, and there were 
no signiﬁ cant diﬀ erences between the vaccine and 
placebo groups in terms of the proportions experiencing 
reactions of any severity (table 4) or unsolicited adverse 
events (appendix p 2). No signiﬁ cant diﬀ erences were 
noted in occurrence of solicited reactions in the extended 
safety subset (appendix p 4).
Nine (1%) participants experienced protocol-deﬁ ned 
wheezing illness, with no signiﬁ cant diﬀ erences in 
occurrence between vaccine groups (table 4). Serious 
adverse events occurred in 14 children; seven in each of 
the vaccine (1%) and placebo (1%) groups (appendix p 5). 
All serious adverse events were considered unrelated to 
vaccination. Two girls, both aged 2 years, died. Both had 
received live attenuated inﬂ uenza vaccine, and causes of 
death were anasarca 12 days postvaccination and 
malnutrition 70 days postvaccination.
Discussion
Among this low-resource paediatric population in sub-
Saharan Africa, symptomatic inﬂ uenza infection was 
common, with an overall attack rate of about 20%. 
Although live attenuated inﬂ uenza vaccine was well 
tolerated, a single dose did not provide protection against 
symptomatic laboratory-conﬁ rmed inﬂ uenza for all 
strains or for the predominant vaccine-matched strain, 
H1N1pdm09. Eﬃ  cacy was also not found for inﬂ uenza B 
strains, although attack rates were low for the 
vaccine-matched B lineage. There were insuﬃ  cient 
H3N2 cases to calculate vaccine strain-speciﬁ c eﬃ  cacy 
for that subtype. Although nearly half of participants had 
been previously vaccinated with trivalent inactivated 
inﬂ uenza vaccine, randomisation ensured equal 
distribution of this factor to study groups in this trial, 
and thus it should not have biased eﬃ  cacy results. The 
study was carefully monitored throughout, and after the 
results were known, we did an additional audit of the site 
and a validation of real-time RT-PCR testing by the 
Senegal National Inﬂ uenza Center laboratory. These 
revealed no concerns which would call into question the 
ﬁ ndings of this trial.
The absence of eﬃ  cacy against strain-matched, 
laboratory-conﬁ rmed symptomatic inﬂ uenza illness in 
this study contrasts with the ﬁ ndings of a similar study 
conducted in the same season with a single dose 
of Nasovac-S among children aged 2–4 years in 
Bangladesh.13 In Bangladesh, H1N1pdm09 and H3N2 
were the predominant strains, with attack rates of 3·6% 
and 12·3% in the placebo group, respectively, and 
vaccine eﬃ  cacy of 50·0% (95% CI 9·2–72·5) against 
H1N1pdm09 and 60·4% (44·8–71·6) against H3N2. The 
reasons for the discrepancy between eﬃ  cacy estimates 
in these two studies are unclear. It is unlikely that 
Live attenuated inﬂ uenza vaccine (n=1171) Placebo (n=587)
Mild Moderate Severe All* Mild Moderate Severe All*
Local and systemic reactions in ﬁ rst 7 days following vaccination
Fever (measured ≥38ºC) 2 (0·2%) 2 (0·2%) 1 (0·1%) 5 (0·4%) 1 (0·2%) 3 (0·5%) 0 (0·0%) 4 (0·7%)
Nasal congestion 41 (3·5%) 0 (0·0%) 0 (0·0%) 41 (3·5%) 16 (2·7%) 0 (0·0%) 0 (0·0%) 16 (2·7%)
Runny nose 199 (17·0%) 2 (0·2%) 0 (0·0%) 201 (17·1%) 95 (16·2%) 0 (0·0%) 0 (0·0%) 95 (16·2%)
Stuﬀ y nose 18 (1·5%) 0 (0·0%) 0 (0·0%) 18 (1·5%) 9 (1·5%) 0 (0·0%) 0 (0·0%) 9 (1·5%)
Cough 110 (9·4%) 4 (0·3%) 0 (0·0%) 114 (9·7%) 58 (9·9%) 0 (0·0%) 0 (0·0%) 58 (9·9%)
Sore throat 4 (0·3%) 0 (0·0%) 0 (0·0%) 4 (0·3%) 4 (0·7%) 1 (0·2%) 0 (0·0%) 5 (0·9%)
Ear pain 6 (0·5%) 1 (0·1%) 0 (0·0%) 7 (0·6%) 2 (0·3%) 0 (0·0%) 0 (0·0%) 2 (0·3%)
Headache 14 (1·2%) 0 (0·0%) 0 (0·0%) 14 (1·2%) 7 (1·2%) 0 (0·0%) 0 (0·0%) 7 (1·2%)
Vomiting 11 (0·9%) 1 (0·1%) 0 (0·0%) 12 (1·0%) 6 (1·0%) 0 (0·0%) 0 (0·0%) 6 (1·0%)
Chills 3 (0·3%) 0 (0·0%) 0 (0·0%) 3 (0·3%) 1 (0·2%) 0 (0·0%) 0 (0·0%) 1 (0·2%)
Irritability/decreased 
activity
14 (1·2%) 2 (0·2%) 0 (0·0%) 16 (1·4%) 7 (1·2%) 1 (0·2%) 0 (0·0%) 8 (1·4%)
Muscle/joint pain 3 (0·3%) 0 (0·0%) 0 (0·0%) 3 (0·3%) 1 (0·2%) 0 (0·0%) 0 (0·0%) 1 (0·2%)
Tachypnoea 
(≥40 breaths per min)
1 (0·1%) 0 (0·0%) 0 (0·0%) 1 (0·1%) 0 (0·0%) 1 (0·2%) 0 (0·0%) 1 (0·2%)
Protocol-deﬁ ned wheezing illness by study period
Days 0–7 0 (0·0%) 0 (0·0%) 0 (0·0%) 0 (0·0%) 0 (0·0%) 0 (0·0%) 0 (0·0%) 0 (0·0%)
Days 8–42 0 (0·0%) 0 (0·0%) 0 (0·0%) 0 (0·0%) 1 (0·2%) 0 (0·0%) 0 (0·0%) 1 (0·2%)
Day 43–6+ months 3 (0·3%) 1 (0·1%) 0 (0·0%) 4 (0·3%) 2 (0·3%) 2 (0·3%) 0 (0·0%) 4 (0·7%)
Anytime 3 (0·3%) 1 (0·1%) 0 (0·0%) 4 (0·3%) 3 (0·5%) 2 (0·3%) 0 (0·0%) 5 (0·9%)
*No signiﬁ cant diﬀ erences using Fisher’s exact test (two-sided p value was never <0·05) between live attenuated inﬂ uenza vaccine and placebo for events of any severity. 
Table 4: Local and systemic reactions in the first 7 days after vaccination and protocol-defined wheezing illness occurring throughout the trial, total vaccinated cohort
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vaccine potency accounted for the eﬃ  cacy diﬀ erences 
given that the same lot of lyophilised vaccine was used 
for both studies. In fact, potency of shelf stocks of 
vaccine had been assessed monthly by Serum Institute 
of India, and in June, 2013, 9 months after manufacture, 
the A/California H1N1pdm09 component had a 50% egg 
infectious dose (EID50) of 10⁷·⁵³². Cold chain, vaccine 
reconstitution, and administration were carefully 
monitored at both sites.
Diﬀ erences in previous history of inﬂ uenza exposure 
could exist in the Senegal and Bangladesh populations. 
Although we do not have prevaccination serological data 
to test this hypothesis, in a concurrent trial of inactivated 
inﬂ uenza vaccines that we did in the neighbouring 
village of Niakhar (NCT01819155), baseline serological 
data showed that less than 25% of children younger 
than 6 years had evidence of previous exposure 
to H1N1pdm09, as determined by haemagglutinin 
antibody levels of >1:10 to that strain. Most of that 
seropositivity was focused in the older age groups, 
consistent with Senegal’s national surveillance data, 
showing extensive H1N1pdm09 circulation in early 
2010, and low levels of circulation later in 2011 and in 
2012, the years before this study. Thus, it is likely that 
most participants in this study were naive to the H1N1 
strain and would not have had antibodies that could 
have interfered with replication of this live vaccine virus 
strain. Even stratiﬁ cation by previous vaccination with 
inactivated inﬂ uenza vaccine 2–3 years before this study 
showed no signiﬁ cant eﬃ  cacy.
Ecology of the nasopharynx or nutritional deﬁ ciencies 
might diﬀ erentially aﬀ ect the ability of the vaccine virus 
to infect or the recipient to mount an immune response 
and, therefore, the performance of vaccine in these two 
populations. Although post-hoc analyses stratifying 
eﬃ  cacy by measures of malnutrition in this study 
population showed no eﬀ ect of nutritional status, other 
unmeasured micronutrient deﬁ ciencies might be 
important. Whether the history of recent oral polio 
vaccine receipt in participants in Senegal could have 
adversely aﬀ ected the performance of the live attenuated 
inﬂ uenza vaccine is also unknown. Previously, a study of 
oral polio vaccine given concomitantly with the Ann 
Arbor-based live attenuated inﬂ uenza vaccine showed 
no eﬀ ect on antibody responses as determined by 
haemagglutination inhibition assay.14 However, no 
studies have determined the eﬀ ects on the immuno-
genicity of live attenuated inﬂ uenza vaccine with oral 
polio vaccine use in the prior 30 days or using alternative 
measures of immune response.
In this study, vaccine virus of at least one strain was 
detected in 80% of live attenuated inﬂ uenza vaccine 
recipients 2–4 days after administration. Since the 
mucociliary clearance rate is minutes, not days,15 we 
believe that our results are evidence of viral replication 
and that vaccine was viable at the time of administration 
in most recipients. However, detection of H1N1pdm09 
was much lower than the other two vaccine strains. 
Although this low detection rate in Senegal stands in 
contrast to studies in Russia16 and Bangladesh17 with 
monovalent and trivalent formulations, respectively, 
where no H1N1pdm09 could be detected in nasal swabs 
or washes postvaccination, one study in the USA with 
initial trivalent live attenuated inﬂ uenza vaccine 
containing A/California (H1N1) did ﬁ nd a substantial 
proportion of children (9/13) shed H1N1pdm09 after 
receipt of one dose.18 As mentioned earlier, diﬀ erences in 
exposure history might exist between the Senegal and 
Bangladesh populations, and national surveillance data 
indicate that H1N1pdm09 circulation has been limited 
since the ﬁ rst wave of the pandemic in Senegal in 
early 2010. Prior immunity to vaccine strains has been 
shown to reduce live attenuated inﬂ uenza vaccine viral 
shedding.19 Previous receipt of inﬂ uenza vaccine has also 
been shown to inhibit shedding,18 although in that study 
previous vaccination was only 1 month prior and previous 
receipt of live attenuated inﬂ uenza vaccine reduced 
shedding more than previous receipt of inactivated 
vaccine. Additionally, the earlier Bangladesh safety study 
used an earlier formulation of trivalent vaccine, and 
vaccine strains can diﬀ erently interfere with each other 
depending on the formulation.20 Nonetheless, we are 
unable to explain why we were able to detect 
H1N1pdm09 vaccine virus postvaccination in about a 
ﬁ fth of recipients and yet measure no eﬃ  cacy.
Although we assessed infectivity of vaccine virus, a 
major limitation of this study is its absence of 
immunological measurements. Standard immunogenicity 
measures following receipt of live attenuated inﬂ uenza 
vaccine have lacked correlation with eﬃ  cacy, and clinical 
eﬃ  cacy studies are the standard for licensure and vaccine 
policy determination.21,22 One study described cell-mediated 
immunity as determined by ELISPOT assays that measure 
γ interferon as correlating with protection following live 
attenuated inﬂ uenza vaccine in children; however, the 
results have not been corroborated and this measurement 
is diﬃ  cult in remote ﬁ eld settings and among children.23 
A recent study of children aged 2–9 years further 
highlights the diﬃ  culty in identifying the immunological 
basis for protection by live attenuated inﬂ uenza vaccine;24 
the study could not identify such a mechanism in a live 
attenuated inﬂ uenza vaccine challenge model. Regardless, 
had we done mucosal or serum immunologic assays, we 
might at least have been able to conﬁ rm that vaccinees 
were responding immunologically in some way to live 
attenuated inﬂ uenza vaccine. Another limitation is that 
we did not assess the protection of two doses of this 
vaccine. Live attenuated inﬂ uenza vaccines based on Ann 
Arbor master donor viruses (FluMist/Fluenz) are licensed 
beginning at 2 years of age, and two doses are 
recommended for children receiving inﬂ uenza vaccine for 
the ﬁ rst time.25  The Russian-derived vaccines are licensed 
for single dose administration. Although comparative 
studies of one versus two doses of live attenuated inﬂ uenza 
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vaccines based on Russian-derived master donor viruses 
have not been done, studies of the Ann Arbor-based 
vaccines suggest that eﬃ  cacy can be achieved after one 
dose, and might be improved by a second dose.8,26,27 
However, an observational study in a broadly aged 
population in India found that Serum Institute of India’s 
monovalent H1N1pdm09 vaccine had high eﬀ ectiveness 
with only one dose.28 Although only half of the young 
children in this study in Senegal were inﬂ uenza vaccine 
naive, whether a second dose of Nasovac-S could have 
provided eﬃ  cacy to those either naive or previously 
exposed to inﬂ uenza vaccine is uncertain.
 Several observational studies of FluMist in the USA in 
2013–14 reported reduced eﬀ ectiveness against the 
current H1N1pdm09 among young children aged 
2–8 years, with eﬀ ectiveness against B preserved.29 
Unfortunately, in view of the absence of suﬃ  cient 
circulating H3N2 and matched B-lineage in Senegal, we 
cannot determine whether the absence of eﬃ  cacy in this 
study was strain-speciﬁ c or more generalised. One 
hypothesis for the US ﬁ ndings in 2013–14 is that the 
H1N1pdm09 strain used for vaccine manufacture might 
not have been optimal because it contained a glutamic 
acid at position 47 (E47) in the haemagglutinin stalk that 
made it less thermally stable and infectious in ferrets 
than A/H1N1 (2009) circulating globally today.30 In early 
2015, the manufacturer of FluMist reported that it would 
replace the A/California (H1N1) strain with an 
antigenically similar strain with a more stable 
haemagglutinin.29 However, the US CDC’s eﬀ ectiveness 
study for 2015–16, a season when H1N1pdm09 
predominated,31 again showed no eﬀ ectiveness of live 
attenuated inﬂ uenza vaccine in mid-year analyses, 
leading the US Advisory Committee on Immunization 
Practices to recommend that the live attenuated inﬂ uenza 
vaccine not be used in the USA for 2016–17.32 Confusing 
the issue further is that ﬁ ndings in other studies, other 
countries, and in other years have shown variable levels 
of eﬀ ectiveness of live attenuated inﬂ uenza vaccine 
against H1N1pdm09.33 Serum Institute of India’s live 
attenuated inﬂ uenza vaccine used in Senegal and the 
parallel Bangladesh trial13 also contained the E47 residue, 
so it is unclear how this contributed to the ﬁ nding of no 
eﬃ  cacy against H1N1pdm09 in Senegal given that 
eﬃ  cacy was demonstrated with this vaccine in the 
Bangladesh trial. Finally, although standard antigenic 
techniques indicated circulating H1N1pdm09 was 
matched to vaccine, we did not sequence isolates; 
however, a study in Canada showed that eﬀ ectiveness 
was preserved for current sequence changes hypothesised 
to result in reduced match to vaccine.3 4
The vaccine was safe and well tolerated, with fever and 
systemic symptoms being uncommon in the 7 days 
after vaccination. Local symptoms, including nasal 
congestion, runny nose, and cough, were common 
among both vaccine and placebo recipients, with no 
imbalances between groups. These safety results are 
similar to those reported in Bangladesh during both a 
phase 2 study and the aforementioned eﬃ  cacy trial 
there.13,35 In view of the association of wheezing and 
admissions to hospital noted among children younger 
than 2 years who were vaccinated with FluMist,36 we 
carefully monitored participants for wheezing illness 
using a standardised deﬁ nition. Incidence of wheezing 
was overall low in this population, and we did not 
observe diﬀ erences between the vaccine and placebo 
groups. These safety ﬁ ndings are reassuring, particularly 
because prelicensure trials in Russia pre-dated the 
FluMist ﬁ nding and were not designed to identify 
wheezing illness as a solicited event.
Our study corroborates several years of inﬂ uenza 
surveillance in this rural community in Senegal, which 
show that inﬂ uenza illness is common in young 
children.9,37–39 Furthermore, in most years in this tropical 
setting, multiple strains circulate and for extended 
periods. During the period of this study, vaccine-
mismatched inﬂ uenza B was the predominant circulating 
strain, supporting the need to further investigate the use 
of quadrivalent vaccines containing both B lineages that 
are already available in many parts of the world. Likewise, 
two doses of live attenuated inﬂ uenza vaccine might be 
necessary for young children in Senegal and elsewhere, 
recognising that a two-dose schedule would be costlier 
and less feasible in low-resource areas of the world.
The Senegal trial of live attenuated inﬂ uenza vaccine 
and its Bangladesh companion contribute essential data 
for the protection aﬀ orded to children by live attenuated 
inﬂ uenza vaccines, especially in low-resource settings. 
Currently, active global discussion on the eﬀ ectiveness of 
live attenuated inﬂ uenza vaccines, especially for the 
current H1N1pdm09 strain, is ongoing and policy makers 
are basing decisions on diﬀ ering results from an array of 
observational studies in the USA, Canada, Europe, and 
elsewhere. Although the Bangladesh eﬃ  cacy trial 
provides conﬁ dence that this live attenuated inﬂ uenza 
vaccine from India can provide protection with a single 
dose, our ﬁ ndings from Senegal are in line with recent 
US CDC studies in which live attenuated inﬂ uenza 
vaccine failed to provide protection against H1N1pdm09. 
Further studies are needed to assess whether our ﬁ ndings 
are speciﬁ c to the H1N1pdm09 strain and whether two 
doses might be eﬃ  cacious, and to better understand the 
performance of live attenuated inﬂ uenza vaccines in 
diverse paediatric populations for whom the burden of 
respiratory disease remains unacceptably high.
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